1 Huttner A, Kronenberg A, Hasse B, Galperine TK. Guidelines der Schweizerischen Gesellschaft für Infektiologie. Harnwegsinfekt (HWI) [Internet]. 2020 [cited 2021 apr xy]. Available from:
https://ssi.guidelines.ch/guideline/2981
2 Altwegg O, Weisskopf S, Mattmüller M, Spieler P, Grandinetti T, Hilfiker A, et al. Akute Blasenentzündung – Behandlung ohne Antibiotika. Prim Hosp Care Allg Inn Med. 2020;20(01):23–8.
doi:10.4414/phc-d.2020.10179.
3 Hilfiker A, Germann M, Altwegg O, Weisskopf S, Tarr P. Rezidivierende Harnwegsinfektionen – Update zu Diagnostik und Prävention. Prim Hosp Care Allg Inn Med. 2021;21(08): 257–63.
4 Zanella M, Schoofs F, Huttner B, Huttner A. Infections urinaires basses non associées aux sondes urinaires chez l’homme. Rev Med Suisse. 2017; 13(558):808–14. French.
5 Schaeffer AJ, Nicolle LE. Urinary Tract Infections in Older Men. Solomon CG, editor. N Engl J Med. 2016;374(6):562–71.
doi:10.1056/NEJMcp1503950
6 Habermacher GM, Chason JT, Schaeffer AJ. Prostatitis / Chronic Pelvic Pain Syndrome. Annu Rev Med. 2006;57(1):195–206.
doi:10.1146/annurev.med.57.011205.135654.
7 Hooton TM. Uncomplicated Urinary Tract Infection. N Engl J Med. 2012;366(11):1028–37.
doi:10.1056/NEJMcp1104429.
8 Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-Based Epidemiologic Analysis of Acute Pyelonephritis. Clinical Infectious Diseases. 2007;45(3):273–80.
doi:10.1086/519268.
9 Krieger JN, Ross SO, Simonsen JM. Urinary tract infections in healthy university men. J Urol. 1993;149(5):1046–48.
doi:10.1016/s0022-5347(17)36292-4
10 Vorland LR, Carlson K, Aalen O. An epidemiological survey of urinary tract infections among outpatients in Northern Norway. Scand J Infect Dis. 1985;17(3):277–83.
doi:10.3109/inf.1985.17.issue-3.06.
11 Hooton TM, Stapleton AE, Roberts PL, Winter C, Scholes D, Bavendam T, et al. Perineal Anatomy and Urine-Voiding Characteristics of Young Women with and without Recurrent Urinary Tract Infections. Clin Infect Dis. 1999;29(6):1600–1.
doi:10.1086/313528.
12 Krieger JN. Urinary tract infections: What’s new? J Urol. 2002;168(6):2351–58.
doi:10.1097/01.ju.0000037620.30988.b2.
13 Lipsky B. Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis and treatment. Ann Intern Med. 1989;110(2):138–50.
14 Hasse B, Huttner A, Huttner B, Egger M, Zanetti G, Marschall J, et al. Behandlung von unkomplizierten Harnwegsinfektionen [Internet]. 2014 [cited 2021 apr xy]. Available from:
https://www.sginf.ch/ssi/images/ssi/guidelines/Guidelines_d_HWI_CH_2014_05_22.pdf10.5167/uzh-106675
15 Köves B, Cai T, Veeratterapillay R, Pickard R, Seisen T, Lam TB, et al. Benefits and Harms of Treatment of Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis by the European Association of Urology Urological Infection Guidelines Panel. European Urology. 2017;72(6):865–68.
doi:10.1016/j.eururo.2017.07.014.
16 Tarr P, Baumann K, Wallnöfer A, Zimmerli F, Maritz D, Burri U, et al. Akute Harnwegsinfektionen, Teil 1: HWI in der Praxis. Swiss Medical Forum – Schweizerisches Medizin-Forum. 2013;13(24):467–71.
doi:10.4414/smf.2013.01543.
17 Burkett E, Carpenter CR, Arendts G, Hullick C, Paterson DL, Caterino JM. Diagnosis of urinary tract infection in older persons in the emergency department: To pee or not to pee, that is the question. Emerg Med Australas. 2019;31(5):856–62.
doi:10.1111/1742-6723.13376.
18 Ulleryd P, Zackrisson B, Aus G, Bergdahl S, Hugosson J, Sandberg T. Selective urological evaluation in men with febrile urinary tract infection. BJUI. 2001;88(1):15–20.
doi:10.1046/j.1464-410x.2001.02252.x.
19 Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. Amoxicillin-Clavulanate vs Ciprofloxacin for the Treatment of Uncomplicated Cystitis in Women: A Randomized Trial. JAMA. 2005;293(8):949–55.
doi:10.1001/jama.293.8.949.
20 Hooton TM, Roberts PL, Stapleton AE. Cefpodoxime vs Ciprofloxacin for Short-Course Treatment of Acute Uncomplicated Cystitis: A Randomized Trial. JAMA. 2012;307(6):583–89.
doi:10.1001/jama.2012.80.
21 Goto T, Makinose S, Ohi Y, Yamauchi D, Kayajima T, Nagayama K, et al. Diffusion of Piperacillin, Cefotiam, Minocycline, Amikacin and Ofloxacin into the Prostate. Int J Urol. 1998;5(3):243–46.
doi:10.1111/j.1442-2042.1998.tb00597.x.
22 Pannek J, Pannek-Rademacher S, Wöllner J. Treatment of Complicated Urinary Tract Infections in Individuals with Chronic Neurogenic Lower Urinary Tract Dysfunction: Are Antibiotics Mandatory? Urol Int. 2018;100(4):434–39.
doi:10.1159/000487245.
23 Pannek J, Pannek-Rademacher S, Jus MS, Wöllner J, Krebs J. Usefulness of classical homeopathy for the prophylaxis of recurrent urinary tract infections in individuals with chronic neurogenic lower urinary tract dysfunction. J Spinal Cord Med. 2019;42(4):453–59.
doi:10.1080/10790268.2018.1440692.
24 Datta R. Frequency of Infection during Fever Episodes among Long-Term Care Residents. J Gerontol Geriatr Res. 2018;7(2):467.
doi:10.4172/2167-7182.1000467.
25 Su S-B, Wang J-N, Lu C-W, Guo H-R. Reducing Urinary Tract Infections among Female Clean Room Workers. Women’s Health. 2006;15(7):870–76.
doi:10.1089/jwh.2006.15.870.
25a Drekonja DM, Trautner B, Amundson C, Kuskowski M, Johnson JR. Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial. JAMA. 2021 Jul 27;326(4):324-331.
doi: 10.1001/jama.2021.9899.
26 Drekonja DM, Rector TS, Cutting A, Johnson JR. Urinary Tract Infection in Male Veterans: Treatment Patterns and Outcomes. JAMA Intern Med. 2013;173(1):62–8.
doi:10.1001/2013.jamainternmed.829.
27 Cai T, Mazzoli S, Mondaini N, Meacci F, Nesi G, D’Elia C, et al. The Role of Asymptomatic Bacteriuria in Young Women With Recurrent Urinary Tract Infections: To Treat or Not to Treat? Clin Infect Dis. 2012;55(6):771–77.
doi:10.1093/cid/cis534.
28 Finucane TE. ‘Urinary Tract Infection’ and the Microbiome. The American Journal of Medicine. 2017;130(3):e97–8.
doi:10.1016/j.amjmed.2016.08.018.
29 Foxman B. Editorial Commentary: Extended-Spectrum-Lactamase-Producing Escherichia coli in the United States: Time to Rethink Empirical Treatment for Suspected E. coli Infections? Clin Infect Dis. 2013;56(5):649–51.
30 Nicolle L, Bradley S, Colgan R, Rice J, Schaeffer A, Hooton T. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40(5):643–54.
doi:10.1086/427507.
31 Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial. Clin Infect Dis. 2019;69(7):1091–98.
doi:10.1093/cid/ciy1054.
31a Von Dach E, Albrich WC, Brunel AS, Prendki V, Cuvelier C, Flury D, et al. Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial. JAMA. 2020 Jun 2;323(21):2160-2169.
doi: 10.1001/jama.2020.6348.
32 Orr PH, Nicolle LE, Duckworth H, Brunka J, Kennedy J, Murray D, et al. Febrile urinary infection in the institutionalized elderly. Am J Med. 1996;100(1):71–7.
doi:10.1016/S0002-9343(96)90014-5.
33 McKenzie R, Stewart MT, Bellantoni MF, Finucane TE. Bacteriuria in Individuals Who Become Delirious. Am J Med. 2014;127(4):255–57.
doi:10.1016/j.amjmed.2013.10.016.
34 Lipsky BA, Byren I, Hoey CT. Treatment of Bacterial Prostatitis. Clin Infect Dis. 2010;50(12):1641–52.
doi:10.1086/652861.
35 Nickel JC. Prostatitis. CUAJ. 2011;5(5):306–15.
doi:10.5489/cuaj.11211.
36 Brede CM, Shoskes DA. The etiology and management of acute prostatitis. Nat Rev Urol. 2011;8(4):207–12.
doi:10.1038/nrurol.2011.22.
37 Touma N, Nickel J. Prostatitis and chronic pelvic pain syndrome in men. Med Clin North Am. 95(1):75–86.
doi:10.1016/j.mcna.2010.08.019.
38 Coker TJ, Dierfeldt DM. Acute Bacterial Prostatitis: Diagnosis and Management. Am Fam Physician. 2016;93(2):114–20.
39 Tchetgen M-BN, Oesterling J. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am. 1997;24(2):283–91.
doi:10.1016/s0094-0143(05)70374-8.
40 Schweizerische Gesellschaft für Urologie. Prostata: Kleine Drüse – grosse Bedeutung. Informationen über die häufigen Erkrankungen für Betroffene und Interessierte [Internet]. 2013 [cited 2021 apr xy]. Available from:
https://swissurology.ch/fileadmin/user_upload/oeffentlich/aerzte_fachpersonal/aktuell/ast_prostatabroschuere_praesentation10.pdf
41 Centers for Disease Control and Prevention. 2015 Sexually Transmitted Diseases Treatment Guidelines [Internet]. 2015 [cited 2021 apr xy]. Available from:
https://www.cdc.gov/std/tg2015/default.htm
42 Krieger JN, Riley DE, Roberts MC, Berger RE. Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis. J Clin Microbiol. 1996;34(12):3120–28.
doi:10.1128/JCM.34.12.3120-3128.1996.
43 Schwenke J, Schaub R, Tarr P. Update Antibiotikaresistenzen 2018 für die Praxis. Prim Hosp Care Allg Inn Med. 2018;18(21):376–80.
doi:10.4414/phc-d.2018.01839.
44 Llewelyn MJ, Fitzpatrick JM, Darwin E, Tonkin-Crine S, Gorton C, Paul J, et al. The antibiotic course has had its day. BMJ. 2017;358:j3418.
doi:10.1136/bmj.j3418.
45 Zani EL, Clark OAC, Rodrigues Netto Jr N. Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev. 2011;(5).
doi: 10.1002/14651858.CD006576.pub2.
46 Senn L, Vuichard D, Widmer A, Zanetti G, Kuster S. Aktualisierte Empfehlungen zur perioperativen Antibiotikaprophylaxe in der Schweiz, 2015. Swissnoso bulletin [Internet]. 2015 [cited 2021 apr xy]. Available from:
www. swissnoso.ch/fileadmin/swissnoso/Dokumente/6_Publikationen/Bulletin_ Artikel_D/v20_1_2015-09_Swissnoso_ Bulletin_de.pdf
47 Roberts MJ, Williamson DA, Hadway P, Doi SAR, Gardiner RA, Paterson DL. Baseline prevalence of antimicrobial resistance and subsequent infection following prostate biopsy using empirical or altered prophylaxis: A bias-adjusted meta-analysis. Int J Antimicrob Agents. 2014;43(4):301–9.
doi:10.1016/j.ijantimicag.2014.01.008.
48 Wagenlehner F, Oostrum E van, Tenke P, Çek M, Grabe M, Wullt B, et al. Infective Complications After Prostate Biopsy: Outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, A Prospective Multinational Multicentre Prostate Biopsy Study. Eur Urol. 2013;63(3):521–27.
doi: 10.1016/j.eururo.2012.06.003.
49 Liss MA, Ehdaie B, Loeb S, Meng MV, Raman JD, Spears V. An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy. J Urol. 2017;198(2):329–34.
doi:10.1016/j.juro.2017.01.103.
50 Jiang P, Liss MA, Szabo RJ. Targeted Antimicrobial Prophylaxis Does Not Always Prevent Sepsis after Transrectal Prostate Biopsy. J Urol. 2018;200(2):361–68.
doi:10.1016/j.juro.2018.03.078.
51 Bonkat G, Pilatz A, Wagenlehner F. Time to Adapt Our Practice? The European Commission Has Restricted the Use of Fluoroquinolones since March 2019. Eur Urol. 2019;76(3):273–75.
doi:10.1016/j.eururo.2019.06.011.
52 European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. Quinolone and fluoroquinolone 2019 [Internet]. 2019 [cited 2021 apr xy]. Available from:
https://www.ema.europa.eu/en/documents/referral/quinolone-fluoroquinolone-article-31-referral-disabling-potentially-permanent-side-effects-lead_en.pdf
53 Pilatz A, Dimitropoulos K, Veeratterapillay R, Yuan Y, Omar MI, MacLennan S, et al. Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. J Urol. 2020;
doi:10.1097/JU.0000000000000814.
54 Pilatz A, Veeratterapillay R, Köves B, Cai T, Bartoletti R, Wagenlehner F, et al. Update on Strategies to Reduce Infectious Complications After Prostate Biopsy. European Urology Focus. 2019;5(1):20–8.
doi:10.1016/j.euf.2018.11.009.
55 Johansen T, Zahl P, Baco E, Bartoletti R, Bonkat G, Bruyere F. Antibiotic resistance, hospitalizations, and mortality related to prostate biopsy: first report from the Norwegian Patient Registry. World J Urol. 2020;38(1):17–26.
doi:10.1007/s00345-019-02837-0.
56 Bennett HY, Roberts MJ, Doi SAR, Gardiner RA. The global burden of major infectious complications following prostate biopsy. Epidemiol Infect. 2016;144(8):1784–91.
doi:10.1017/S0950268815002885.
57 Taylor S, Margolick J, Abughosh Z, Goldenberg SL, Lange D, Bowie WR, et al. Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy: Ciprofloxacin resistance and prostate biopsy. BJU Int. 2013;111(6):946–53.
doi:10.1111/j.1464-410X.2012.11637.x.
58 Williamson DA, Barrett LK, Rogers BA, Freeman JT, Hadway P, Paterson DL. Infectious Complications Following Transrectal Ultrasound-Guided Prostate Biopsy: New Challenges in the Era of Multidrug-Resistant Escherichia coli. Clin Infect Dis. 2013;57(2):267–74.
doi:10.1093/cid/cit193.
59 Saade EA, Suwantara N, Zabarsky TF, Wilson B, Donskey CJ. Fluoroquinolone-Resistant Escherichia coli Infections after Transrectal Biopsy of the Prostate in the Veterans Affairs Healthcare System. PAI. 2016;1(2):243–57.
doi:10.20411/pai.v1i2.123.
60 Roberts MJ, Bennett HY, Harris PN, Holmes M, Grummet J, Naber K, et al. Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches. J Urol. 2017;104:11–21.
doi:10.1016/j.urology.2016.12.011.
61 Clemens JQ, Meenan RT, O’Keeffe Rosetti MC, Kimes T, Calhoun EA. Prevalence of and Risk Factors for Prostatitis: Population Based Assessment Using Physician Assigned Diagnoses. J Urol. 2007;178(4 Pt 1):1333–37.
doi:10.1016/j.juro.2007.05.140.
62 Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. Examination of the Relationship Between Symptoms of Prostatitis and Histological Inflammation: Baseline Data From the REDUCE Chemoprevention Trial. J Urol. 2007;178(3 Pt 1):896–900.
doi:10.1016/j.juro.2007.05.041.
63 Schaeffer AJ. Chronic Prostatitis and the Chronic Pelvic Pain Syndrome. N Engl J Med. 2006;355(16):1690–98.
doi:10.1056/NEJMcp060423.
64 Horner PJ, Blee K, Falk L, Meijden W van der, Moi H. 2016 European guideline on the management of non-gonococcal urethritis. Int J STD AIDS. 2016;27(11):928–37.
doi:10.1177/0956462416648585.
65 Bradshaw CS, Tabrizi SN, Read TRH, Garland SM, Hopkins CA, Moss LM, et al. Etiologies of Nongonococcal Urethritis: Bacteria, Viruses, and the Association with Orogenital Exposure. J Infect Dis. 2006;193(3):336–45.
doi:10.1086/499434.
66 Krieger JN, Ross SO, Riley DE. Chronic prostatitis: epidemiology and role of infection. Urology. 2002;60(6):8–12.
doi:10.1016/s0090-4295(02)02294-x.
67 Nickel JC, Xiang J. Clinical Significance of Nontraditional Bacterial Uropathogens in the Management of Chronic Prostatitis. J Urol. 2008;179(4):1391–95. doi:10.1016/j.juro.2007.11.081.
68 Magri V, Marras E, Perletti G. Chronic bacterial prostatitis: enterococcal disease? Clin Infect Dis. 2011;53(12):1306–7.
doi:10.1093/cid/cir709.
69 Park H, Sim S, Lee G. The Presence of Chlamydia Is Associated With Increased Leukocyte Counts and Pain Severity in Men With Chronic Pelvic Pain Syndrome. J Urol. 2015;85(3):574–79.
doi:10.1016/j.urology.2014.11.008.
70 Papeš D, Pasini M, Jerončić A. Detection of sexually transmitted pathogens in patients with chronic prostatitis / chronic pelvic pain: a prospective clinical study. Int J STD AIDS. 2017;28(6):613–15.
doi:10.1177/0956462417691440.
71 Nickel J, Alexander R, Schaeffer A, Landis J, Knauss J, Propert K, et al. Leukocytes and bacteria in men with chronic prostatitis / chronic pelvic pain syndrome compared to asymptomatic controls. J Urol. 2003;170(3):818–22.
doi:10.1097/01.ju.0000082252.49374.e9.
72 Schaeffer AJ, Wu S-C, Tennenberg AM, Kahn JB. Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. J Urol. 2005;174(1):161–64.
doi:10.1097/01.ju.0000162017.24965.2b.
73 Bozeman C, Carver C, Eastham J, Venable D. Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol. 2002;167(4):1723–26.
doi:10.1016/S0022-5347(05)65186-5.
74 Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together [Internet]. 2016 [cited 2021 apr xy]. Available from:
https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain
75 Shoskes DA, Lee C-T, Murphy D, Kefer J, Wood HM. Incidence and Significance of Prostatic Stones in Men with Chronic Prostatitis / Chronic Pelvic Pain Syndrome. J Urol. 2007;70(2):235–38.
doi:10.1016/j.urology.2007.04.008.
76 Geramoutsos I, Gyftopoulos K, Perimenis P, Thanou V, Liagka D, Siamblis D, et al. Clinical Correlation of Prostatic Lithiasis with Chronic Pelvic Pain Syndromes in Young Adults. Eur Urol. 2004;45(3):333–38.
doi:10.1016/j.eururo.2003.09.020.
77 Dhar NB, Shoskes DA. New therapies in chronic prostatitis. Curr Urol Rep. 2007;8(4):313–8.
doi:10.1007/s11934-007-0078-5.
78 Savaria F, Zbinden R, Wüst J, Burnens A, Ledergerber B, Weber R, et al. Antibiotikaresistenzen von E. coli in Urinproben: Prävalenzdaten dreier Laboratorien im Raum Zürich von 1985 bis 2010. Praxis. 2012;101(9):573–79.
doi:10.1024/1661-8157/a000918.
79 Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton DM, Zeglinski PT, et al. Is Fosfomycin a Potential Treatment Alternative for Multidrug-Resistant Gram-Negative Prostatitis? Clin Infect Dis. 2014;58(4):e101–5.
doi:10.1093/cid/cit704.
80 Pronk MJH, Pelger RCM, Baranski AG, Dam A, Arend SM. Cure of chronic prostatitis presumably due to Enterococcus spp and gram-negative bacteria. Eur J Clin Microbiol Infect Dis. 2006;25(4):270–1.
doi:10.1007/s10096-006-0128-9.
81 Cohen JM, Fagin AP, Hariton E, Niska JR, Pierce MW, Kuriyama A, et al. Therapeutic Intervention for Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS): A Systematic Review and Meta-Analysis. Eldabe S, editor. PLoS ONE. 2012;7(8):e41941.
doi:10.1371/journal.pone.0041941.
82 Anothaisintawee T, Attia J, Nickel J, Numthavaj P, McEvoy M, Thakkinstian A. Management of Chronic Prostatitis / Chronic Pelvic Pain Syndrome: A Systematic Review and Network Meta-analysis. JAMA. 2011;305(1):78–86.
doi:10.1001/jama.2010.1913.
83 Alexander RB, Propert KJ, Schaeffer AJ, Landis JR, Nickel JC, O’Leary MP, et al. Ciprofloxacin or Tamsulosin in Men with Chronic Prostatitis / Chronic Pelvic Pain Syndrome. Ann Intern Med. 2004;141(8):581–9.
doi:10.7326/0003-4819-141-8-200410190-00005.
6 Habermacher GM, Chason JT, Schaeffer AJ. Prostatitis/ Chronic Pelvic Pain Syndrome. Annu Rev Med. 2006;57(1):195–206.
doi:10.1146/annurev.med.57.011205.135654.
5 Schaeffer AJ, Nicolle LE. Urinary Tract Infections in Older Men. Solomon CG, editor. N Engl J Med. 2016;374(6):562–71.
doi:10.1056/NEJMcp1503950.
4 Zanella M, Schoofs F, Huttner B, Huttner A. Infections urinaires basses non associées aux sondes urinaires chez l’homme. Rev Med Suisse. 2017;13(558):808–14. French.